Treatment of acquired thrombotic thrombocytopenic without plasma exchange in selected patients under caplacizumab
Linus A. Völker(University of Cologne), Wolfgang Miesbach(Goethe University Frankfurt), PT Brinkkoetter(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Miroslav Krstić(Danube Private University), Jan Menne, Jessica Kaufeld(Medizinische Hochschule Hannover), P. V. Knobl(Medical University of Vienna), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz)
Cited by 1
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
|Blood Cancer Journal|2015|273